Highlights from

ACC 2020

Together with World Congress of Cardiology

Virtual 28 - 30 March 2020

Letter from the Editor

Dear Reader,

The 2020 American College of Cardiology Scientific Sessions occurred in the context of an incredibly challenging period where all were and continue to be impacted by the COVID pandemic. The implications of COVID were broad in that many participants and attendees are on the frontline helping patients; all of us are impacted personally no matter where we live; travel was impossible; and scientific priorities were largely focused on COVID. These implications rapidly unfolded in the weeks preceding the planned Scientific Sessions in Chicago and required the rapid and dynamic pivot to a virtual meeting that would enable the scientific community to come together and disseminate high-quality science in an effective format. In spite of these challenges, landmark trials including VOYAGER PAD, VICTORIA, and CARVAGGIO as well as many other studies were presented online with panel discussion, QA, and dynamic chat.

In the following pages you will find a comprehensive review of this landmark virtual meeting and summaries of pivotal trials and impactful studies. We hope you find this report to be useful and informative. Thank you for your interest and most of all we wish you all the best, hope you and your families are safe and healthy, and express our thanks to all who are doing what they can to help in this critical and challenging time.

Marc Bonaca

Biography Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement: Grant support to BWH from AstraZeneca, MedImmune, Merck, Pfizer Grant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi

Top image: @ iStockPhoto: MStudioImages

Article image: Medicom

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.